Related Experiment Videos
Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency
Victor W van Beusechem1, Petra B van den Doel, Jacques Grill
1Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center, 1081 HV Amsterdam, the Netherlands. vw.van_beusechem.oncol@med.vu.nl
Cancer Research
|November 5, 2002
Summary
Restoring the p53 pathway in cancer cells enhances the effectiveness of conditionally replicative adenoviruses (CRAds). This p53-expressing CRAd, AdDelta24-p53, significantly boosts oncolytic potency for treating diverse human cancers.
Area of Science:
- Oncolytic virotherapy
- Cancer biology
- Gene therapy
Background:
- Conditionally replicative adenoviruses (CRAds) are potential anticancer agents, relying on efficient replication and cancer cell lysis (oncolysis).
- Adenovirus-mediated cell death often involves the tumor suppressor protein p53, but many cancers have nonfunctional p53 pathways, limiting CRAd efficacy.
- Restoring p53 function could enhance CRAd-induced oncolysis in p53-deficient cancers.
Purpose of the Study:
- To investigate if restoring the p53-dependent cell death pathway enhances CRAd-induced oncolysis.
- To develop and evaluate a novel CRAd expressing functional p53 for improved cancer treatment.
Main Methods:
- Exogenous expression of p53 in human cancer cells during adenovirus replication.
- Construction and characterization of a new CRAd, AdDelta24-p53, engineered to express functional p53.
- Testing the oncolytic potency of AdDelta24-p53 on various human cancer cell lines with different p53 statuses.
Main Results:
- Exogenous p53 expression accelerated cancer cell death and increased early virus progeny release.
- p53-enhanced oncolysis was independent of E1A binding to pRb and E3 functions.
- AdDelta24-p53 demonstrated significantly enhanced oncolytic potency (up to >100-fold) across 80% of tested cancer cell lines, irrespective of their p53 status.
Conclusions:
- Restoration of p53-dependent cell death pathways can significantly augment CRAd oncolytic efficacy.
- CRAds engineered to express p53, such as AdDelta24-p53, represent a promising strategy for more effective treatment of a wide range of human cancers.